SequelSEC

Axsome Therapeutics, Inc. AXSM

Pharmaceutical Preparations · CIK 0001579428 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$218.38M
Fiscal year ended 2026-06-30
Operating income
-$49.65M
Fiscal year ended 2026-06-30
Free cash flow
-$33.40M
Fiscal year ended 2026-06-30

Axsome Therapeutics, Inc. (AXSM) reported revenue of $218.38M and net income of -$51.31M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Axsome Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Axsome Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$218.38M$191.20M$196.00M$170.99M$150.04M$121.46M$118.77M$104.76M$87.17M$75.00M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$49.65M-$63.36M-$26.96M-$46.11M-$36.71M-$56.98M-$72.62M-$62.62M-$78.05M-$67.28M
Net income-$51.31M-$64.54M-$28.56M-$47.23M-$47.97M-$59.41M-$74.91M-$64.60M-$79.34M-$68.36M
Research & development$46.23M$52.68M$48.79M$40.16M$49.54M$44.78M$55.01M$45.39M$49.85M$36.83M
Weighted-average diluted sharesshares 51.80Mshares 51.20MUnavailableshares 50.02Mshares 49.44Mshares 48.87MUnavailableshares 48.14Mshares 47.57Mshares 47.39M
Pretax income-$51.19M-$64.54M-$28.13M-$47.23M-$48.93M-$59.41M-$74.83M-$64.60M-$79.34M-$68.36M
Income tax expense$128.00K$0$430.00K$0-$960.00K$0$85.00K$0$0$0
Diluted EPS$-0.99$-1.26Unavailable$-0.94$-0.97$-1.22Unavailable$-1.34$-1.67$-1.44
Selling, general & administrative$208.14M$185.00M$169.30M$150.24M$130.28M$120.79M$113.27M$95.56M$103.55M$98.97M
General & administrative$24.62M$22.02M$18.65M$19.74M$13.23M$11.65M$17.78M$11.59M$12.69M$12.15M
Selling & marketing$164.11M$146.44M$134.54M$114.20M$99.38M$92.29M$79.42M$68.19M$74.56M$71.20M

Balance

Axsome Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$319.85M$305.11M$322.93M$325.27M$303.02M$300.91M$315.35M$327.34M$315.66M$331.44M
Total assets$761.45M$713.61M$689.80M$669.25M$639.78M$596.67M$568.50M$561.46M$548.23M$545.73M
Current assets$656.57M$611.21M$588.99M$565.34M$536.62M$494.63M$485.06M$479.11M$463.03M$460.49M
Total liabilities$678.14M$659.02M$601.51M$595.52M$566.71M$543.47M$511.48M$468.56M$445.37M$401.69M
Current liabilities$460.45M$439.21M$378.84M$360.29M$342.10M$243.91M$230.10M$196.19M$186.57M$144.05M
Total equity incl. NCI$83.30M$54.59M$88.30M$73.73M$73.08M$53.20M$57.02M$92.90M$102.85M$144.04M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$37.88M$31.52M$27.94M$23.77M$18.44M$16.32M$15.73M$14.26M$15.22M$15.58M
Accounts receivable$277.46M$251.06M$224.46M$196.51M$198.82M$161.40M$142.00M$124.10M$120.34M$101.43M
Goodwill$12.04M$12.04M$12.04M$12.04M$12.04M$12.04M$12.04M$12.04M$12.04M$12.04M
Long-term debt$117.96M$117.85M$117.75M$117.64M$117.54M$181.38M$180.71M$180.00M$179.33M$178.69M
Accounts payable$78.97M$106.70M$65.54M$54.23M$91.63M$85.66M$72.00M$64.25M$61.34M$53.79M

Cash flow

Axsome Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$32.95M-$20.70M-$18.65M$1.05M-$32.42M-$43.38M-$26.20M-$18.63M-$30.11M-$53.47M
Capital expenditures$450.00K$121.00K$71.00K$58.00K$13.00K$338.00K$30.00K$90.00K$52.00K$98.00K
Investing cash flow-$450.00K-$121.00K-$71.00K-$58.00K-$13.00K-$338.00K-$30.00K-$90.00K-$52.00K-$98.00K
Financing cash flow$48.15M$2.99M$16.38M$21.27M$34.54M$29.27M$14.24M$30.40M$14.38M-$1.19M
Net change in cash$14.74M-$17.83M-$2.34M$22.26M$2.11M-$14.44M-$11.99M$11.68M-$15.78M-$54.75M
Stock-based compensation$27.15M$23.44M$22.73M$23.10M$24.61M$23.31M$21.99M$21.66M$21.38M$20.19M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Axsome Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$33.40M-$20.82M-$18.72M$988.00K-$32.44M-$43.71M-$26.23M-$18.72M-$30.16M-$53.56M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-22.7%-33.1%-13.8%-27.0%-24.5%-46.9%-61.1%-59.8%-89.5%-89.7%
FCF margin-15.3%-10.9%-9.6%0.6%-21.6%-36.0%-22.1%-17.9%-34.6%-71.4%
SBC / revenue12.4%12.3%11.6%13.5%16.4%19.2%18.5%20.7%24.5%26.9%
Current ratio1.43x1.39x1.55x1.57x1.57x2.03x2.11x2.44x2.48x3.20x
Revenue YoY growth45.5%57.4%65.0%63.2%72.1%62.0%66.0%81.3%86.7%-20.7%
Net margin-23.5%Unavailable-14.6%-27.6%-32.0%Unavailable-63.1%-61.7%UnavailableUnavailable
R&D / revenue21.2%27.6%24.9%23.5%33.0%36.9%46.3%43.3%57.2%49.1%
CapEx / revenue0.2%0.1%0.0%0.0%0.0%0.3%0.0%0.1%0.1%0.1%
Long-term debt / equity1.42xUnavailable1.33x1.60xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AXSM in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-04View SEC filing
10-K · Filed 2026-02-23View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-04View SEC filing
10-Q · Filed 2025-05-05View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2022-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2022-09-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.